For research use only. Not for therapeutic Use.
DLCI-1 is a potent and selective inhibitor of cytochrome P450 2A6 (CYP2A6) with an IC50 value of 0.017 μM. DLCI-1 decreases nicotine self-administration in mice.
KEYWORDS: DLCI-1 | supplier | CYP2A6 inhibitor | DLCI 1 | DLCI1 | CAS [2244569-15-9] | [2244569-14-8] | Non Selective | Cytochrome P450 | Inhibitor | Enzymes | Smoking cessation
| Catalog Number | I047652 |
| CAS Number | 2244569-15-9 |
| Molecular Formula | C12H14N2S.2HCl |
| Purity | ≥95% |
| IUPAC Name | [5-(4-ethylpyridin-3-yl)thiophen-2-yl]methanamine;dihydrochloride |
| InChI | InChI=1S/C12H14N2S.2ClH/c1-2-9-5-6-14-8-11(9)12-4-3-10(7-13)15-12;;/h3-6,8H,2,7,13H2,1H3;2*1H |
| SMILES | CCC1=C(C=NC=C1)C2=CC=C(S2)CN.Cl.Cl |
| Reference | YC Chen et al. The Novel CYP2A6 Inhibitor, DLCI-1, Decreases Nicotine Self-Administration in Mice. J Pharmacol Exp Ther. 2020 Jan;372(1):21-29. TT Denton et al. Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition. J Med Chem. 2018;61(16):7065‐7086. |
